TELIX PHARMACEUTICALS LTD (TLX.AU) stock soared 5.59% during intraday trading on Friday, reflecting strong investor sentiment.
The surge follows the company's release of its full-year revenue results and forward guidance. Telix reported FY revenue of US$803.8 million and provided FY 2026 group revenue guidance of US$950 million to US$970 million, indicating robust expected growth. Additionally, the company reported a non-material loss before tax of US$5.3 million for the period.